Citius Pharmaceuticals (CTXR) Competitors $2.73 +0.15 (+5.81%) (As of 12/17/2024 05:46 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends CTXR vs. IMAB, ELYM, GBIO, HOWL, PYRGF, OVID, FBLG, AVTE, EPIX, and PDSBShould you be buying Citius Pharmaceuticals stock or one of its competitors? The main competitors of Citius Pharmaceuticals include I-Mab (IMAB), Eliem Therapeutics (ELYM), Generation Bio (GBIO), Werewolf Therapeutics (HOWL), PyroGenesis Canada (PYRGF), Ovid Therapeutics (OVID), FibroBiologics (FBLG), Aerovate Therapeutics (AVTE), ESSA Pharma (EPIX), and PDS Biotechnology (PDSB). These companies are all part of the "pharmaceutical products" industry. Citius Pharmaceuticals vs. I-Mab Eliem Therapeutics Generation Bio Werewolf Therapeutics PyroGenesis Canada Ovid Therapeutics FibroBiologics Aerovate Therapeutics ESSA Pharma PDS Biotechnology I-Mab (NASDAQ:IMAB) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends, profitability and community ranking. Which has preferable earnings & valuation, IMAB or CTXR? Citius Pharmaceuticals has lower revenue, but higher earnings than I-Mab. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioI-Mab$3.27M23.54-$206.44MN/AN/ACitius PharmaceuticalsN/AN/A-$32.54M-$6.00-0.46 Does the MarketBeat Community believe in IMAB or CTXR? Citius Pharmaceuticals received 150 more outperform votes than I-Mab when rated by MarketBeat users. However, 64.13% of users gave I-Mab an outperform vote while only 62.20% of users gave Citius Pharmaceuticals an outperform vote. CompanyUnderperformOutperformI-MabOutperform Votes5964.13% Underperform Votes3335.87% Citius PharmaceuticalsOutperform Votes20962.20% Underperform Votes12737.80% Is IMAB or CTXR more profitable? I-Mab's return on equity of 0.00% beat Citius Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets I-MabN/A N/A N/A Citius Pharmaceuticals N/A -44.65%-39.39% Which has more risk & volatility, IMAB or CTXR? I-Mab has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Do insiders and institutionals hold more shares of IMAB or CTXR? 38.4% of I-Mab shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 22.1% of I-Mab shares are owned by insiders. Comparatively, 15.0% of Citius Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media favor IMAB or CTXR? In the previous week, Citius Pharmaceuticals had 1 more articles in the media than I-Mab. MarketBeat recorded 1 mentions for Citius Pharmaceuticals and 0 mentions for I-Mab. I-Mab's average media sentiment score of 0.93 beat Citius Pharmaceuticals' score of 0.43 indicating that I-Mab is being referred to more favorably in the media. Company Overall Sentiment I-Mab Positive Citius Pharmaceuticals Neutral Do analysts recommend IMAB or CTXR? I-Mab presently has a consensus target price of $8.00, suggesting a potential upside of 746.29%. Citius Pharmaceuticals has a consensus target price of $100.00, suggesting a potential upside of 3,563.00%. Given Citius Pharmaceuticals' higher probable upside, analysts clearly believe Citius Pharmaceuticals is more favorable than I-Mab.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score I-Mab 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Citius Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryI-Mab beats Citius Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Ad Porter & CompanyHow to piss off your liberal friends… and profit from itElon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Get Citius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTXR vs. The Competition Export to ExcelMetricCitius PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.74M$6.86B$5.18B$9.31BDividend YieldN/A3.06%4.78%4.06%P/E Ratio-0.4610.75130.2217.53Price / SalesN/A287.791,246.14139.51Price / CashN/A56.6541.2337.95Price / Book0.195.394.884.92Net Income-$32.54M$152.04M$119.65M$225.78M7 Day Performance-10.78%-4.32%16.62%-1.56%1 Month Performance-51.29%2.80%16.34%6.68%1 Year Performance-85.79%17.30%35.38%22.48% Citius Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTXRCitius Pharmaceuticals2.376 of 5 stars$2.73+5.8%$100.00+3,563.0%-86.3%$19.74MN/A-0.4620Short Interest ↑IMABI-Mab3.1206 of 5 stars$0.95-4.6%$8.00+738.3%-32.0%$77.78M$3.27M0.0034ELYMEliem TherapeuticsN/A$2.60-7.8%N/A-11.4%$77.36MN/A-4.9120Positive NewsGap DownGBIOGeneration Bio3.0954 of 5 stars$1.15-1.1%$7.50+554.1%-45.5%$76.59M$18.58M-0.53150Positive NewsGap DownHOWLWerewolf Therapeutics3.8006 of 5 stars$1.70+2.7%$12.00+608.0%-45.2%$75.53M$3.39M-1.0840Short Interest ↓News CoveragePositive NewsPYRGFPyroGenesis CanadaN/A$0.41-0.1%N/A+21.3%$75.46M$9.14M-6.8490OVIDOvid Therapeutics4.4843 of 5 stars$1.06+2.4%$4.04+282.9%-69.2%$74.92M$390,000.000.0060Positive NewsGap DownFBLGFibroBiologics1.6988 of 5 stars$2.13-4.1%$13.00+510.3%N/A$73.82MN/A0.0010Short Interest ↑AVTEAerovate Therapeutics1.372 of 5 stars$2.55+0.8%$2.25-11.8%-85.8%$73.63MN/A-0.8551Short Interest ↓News CoveragePositive NewsEPIXESSA Pharma3.4938 of 5 stars$1.65+0.6%$9.50+475.8%-73.7%$73.21MN/A-2.6550Earnings ReportNews CoveragePositive NewsGap UpPDSBPDS Biotechnology1.3338 of 5 stars$1.93+5.0%$11.67+503.8%-61.6%$72.28MN/A-1.5920 Related Companies and Tools Related Companies IMAB Competitors ELYM Competitors GBIO Competitors HOWL Competitors PYRGF Competitors OVID Competitors FBLG Competitors AVTE Competitors EPIX Competitors PDSB Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CTXR) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTXR Stock Alerts